Nanobiotix S.A. Stock Price, News & Analysis

NANOBIOTIX (NASDAQ: NBTX) announced progress for its Curadigm Nanoprimer platform on Nov 13, 2025: four new patent applications were filed to expand IP; new in vivo preclinical data presented at PODD 2025 showed the Nanoprimer boosted acute and memory immune responses when combined with mRNA lipoplex and peptide vaccines; numerous material transfer agreements are in place to explore external collaborations; and Chemistry, Manufacturing, and Controls (CMC) activities have been launched to support both an initial proprietary pipeline and partners.

Company positions Nanoprimer as a hub for collaborations and internal product development to address extrahepatic IV delivery challenges.

NANOBIOTIX (NASDAQ: NBTX) said company management will participate in a fireside chat at the Jefferies London Healthcare Conference on Monday, November 17, 2025. The session is scheduled for 3:00 PM GMT / 10:00 AM ET / 4:00 PM CET in London.

Presenters listed are Laurent Levy, Chief Executive Officer, and Bart van Rhijn, Chief Financial & Business Officer. The fireside chat will be webcast live from the company’s investors events page, with a replay available after the event.

NANOBIOTIX (NASDAQ: NBTX) announced that company management will participate in investor fireside chats the week of November 10, 2025.

Presentations and presenters:

• UBS Global Healthcare Conference — Monday, November 10, 2025 at 5:00 PM ET / 11:00 PM CET — Palm Beach Gardens, FL — Presenter: Bart van Rhijn, Chief Financial & Business Officer
• Guggenheim Annual Healthcare Innovation Conference — Monday, November 10, 2025 at 4:30 PM ET / 10:30 PM CET — Boston, MA — Presenter: Laurent Levy, Chief Executive Officer
• Stifel Healthcare Conference — Thursday, November 13, 2025 at 8:00 AM ET / 2:00 PM CET — New York, NY — Presenters: Laurent Levy and Bart van Rhijn

All fireside chats will be webcast live from the company Investors events page, with replays available after each event.

NANOBIOTIX (NASDAQ:NBTX) entered a royalty monetization agreement with HealthCare Royalty (HCRx) providing up to $71 million in non-dilutive capital to fund development of JNJ-1900 (NBTXR3) and next‑wave nanotherapeutics. The company will receive $50 million upfront and may receive an additional $21 million one year post‑closing subject to conditions. Repayment is sourced from a portion of royalties and milestones on the first $1 billion of net sales with a capped return of ~$124M if repaid by end of 2030 (1.75x) or ~$178M thereafter (2.5x).

Following the cap, a reduced royalty tail (≤$14.9M/yr) applies for up to 10 years after first US commercial sale. The deal transfers receivables to a French law trust and, assuming full drawdown, extends cash runway into early 2028.

NANOBIOTIX (NASDAQ:NBTX) announced completion of the transfer of sponsorship for the NANORAY-312 Phase 3 head and neck cancer trial (initiated 3Q2024) in the majority of regions and transfer of full operational control to Johnson & Johnson.

Following Nanobiotix's review of the latest information, the Company now estimates that NANORAY-312 interim data will be analyzed and reported in 1H2027 after the requisite number of events and last patient recruitment. Future guidance for NANORAY-312 and other JNJ-1900 (NBTXR3) studies sponsored by J&J will be provided by J&J. Nanobiotix will continue to update on Nanobiotix-sponsored studies and MD Anderson-sponsored trials.

NanoBioTix (Nasdaq: NBTX) provided its voting rights and share capital update dated October 15, 2025. The company reports 48,237,471 shares outstanding (as of September 30, 2025) and a total theoretical number of voting rights of 50,318,257 with 50,296,139 exercisable voting rights. Markets: Euronext Paris (Compartment B) and NasdaqEuronext. ISIN: FR0011341205. This notice fulfills disclosure requirements under French commercial and AMF rules regarding the number of shares and voting rights.

Nanobiotix (NASDAQ: NBTX) has announced promising first data from a Phase 1 study of JNJ-1900 (NBTXR3) in patients with locally advanced esophageal adenocarcinoma. The study, conducted at MD Anderson Cancer Center, demonstrated an 85% disease control rate and 69% objective response rate among 13 patients.

The treatment, combining JNJ-1900 with chemoradiation, showed strong safety profile and confirmed injection feasibility. Key outcomes include 6 complete responses and 3 partial responses. Of 6 patients who underwent surgery, 2 achieved pathological complete response and 4 showed major pathologic response. The recommended Phase 2 dose was established at 33% of gross tumor volume.

The study continues with recruitment of 17 additional patients, exploring both photon and proton chemoradiation combinations.

Nanobiotix (NASDAQ: NBTX) reported its H1 2025 financial results and business updates, highlighting significant progress in its clinical development program for JNJ-1900 (NBTXR3). The company's revenue increased to €26.6 million, up from €9.3 million in H1 2024, primarily due to a €21.2 million non-cash revenue impact from the J&J agreement amendment.

R&D expenses decreased to €14.5 million from €22.0 million, while net loss improved to €5.4 million from €21.9 million year-over-year. Cash position stood at €28.8 million as of June 30, 2025, expected to fund operations into mid-2026. However, the company noted material uncertainty about its going concern status and is in active discussions for non-dilutive financing to extend its cash runway.

Nanobiotix (NASDAQ: NBTX) announced updated Phase 1 results for JNJ-1900 (NBTXR3) in combination with anti-PD-1 therapy for head and neck cancer patients. The study showed promising outcomes in both anti-PD-1 naïve and resistant patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC).

Key findings include a 63% disease control rate and 37% objective response rate in anti-PD-1 naïve patients, while resistant patients showed a 74% disease control rate and 32% objective response rate. The treatment demonstrated strong local control with a 95% aggregate disease control rate in injected lesions across all evaluable patients. Median overall survival reached 15.5 months for naïve patients and 11.4 months for resistant patients.

The treatment was well-tolerated among 103 heavily pre-treated patients, with investigators concluding these promising results warrant further exploration in randomized controlled trials.